Monogenic and Syndromic Obesity

Overview

• The heritability of obesity is estimated between 40-70%, but the genetics of obesity for most individuals is complex and involves the interaction of multiple genes with the environment. There are however several syndromic and non-syndromic forms of obesity that are monogenic and oligogenic that provide insight into the underlying molecular control of food intake and the mechanisms that control ingestive behavior and satiety to regulate body weight. The mode of inheritance is typically autosomal dominant.  

• The Igenomix Monogenic and Syndromic Precision Panel can be used to make a directed and accurate differential diagnosis of obesity, ultimately leading to a better management and prognosis of the disease and its outcomes. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

The Igenomix Monogenic and Syndromic Obesity Precision Panel is indicated for those patients with obesity with or without family history of obesity presenting with the following manifestations: 

• Abnormal weight growth pattern  
• Elevated body mass index  
• Hypertension  
• Type 2 diabetes  
• Metabolic Syndrome 

Clinical Utility

The clinical utility of this panel is: 

• The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
• Early initiation of treatment with a multidisciplinary team for early pharmacologic therapy, surgical intervention, and/or dietary modifications to reduce comorbidities associated with obesity. 
• Risk assessment of asymptomatic family members according to the mode of inheritance. 

Genes & Diseases